Boston
Therapeutics is developing a pipeline of therapeutic molecules based on complex
carbohydrate chemistry. This pipeline currently carries three compounds that
are being fine-tuned and tested in hopes that each will become a commercialized
therapeutic treatment for diabetes.
Drug
candidate PAZ320 is being developed for the prevention of diabetes and related
complications. PAZ320 is a non-systemic, non-toxic, chewable drug candidate
that inhibits the enzymes that release glucose from complex carbohydrates in
foods during digestion. By blocking this release, the drug reduces the amount
of available glucose absorbed through the intestine.
The
company recently began enrollment for phase IIb trial in France to assess the
efficacy and safety of PAZ320 in combination with metformin in patients with
Type 2 diabetes. The company has also began preparation for an application of
an investigational new drug (IND) submission to the U.S. FDA for phase III
trial in the U.S., Europe, Hong Kong, and China to evaluate the effects of
PAZ320 on post-meal glucose levels in patients with Type 2 diabetes.
In
pre-clinical development is IPOXYN™, the company’s injectable therapeutic agent
that utilizes proprietary processes and patented technology to prevent
necrosis, the death of tissue from inadequate blood flow, and treatment of
ischemic conditions that may result in necrosis. Necrosis is the outcome of
severe and acute injury such as from pathological conditions such as heart
attack, brain injuries and stroke, as well as neurodegenerative diseases such
as Alzheimer’s disease, pancreatitis and many others. IPOXYN is targeting both
human and animal tissues and organ systems deprived of oxygen and in need of
metabolic support.
Aside
from a gap in diabetes treatments in humans, Boston Therapeutics also
recognizes the unmet need in the veterinary market for blood replacement and
oxygen delivery due to damage or ischemic tissue as a result of trauma, surgery
anemia or other disease conditions. For this application the company is
developing OXYFEX™, which can serve as the only available oxygen delivery
mechanism for animals suffering ischemia or traumatic and surgical blood loss
events. OXYFEX is also in pre-clinical development.
Boston
Therapeutics continues to advance its compounds to address the estimated 22
million people in the United States currently suffer from, and are enrolled in
treatment for, Type 2 diabetes.
For
more information, visit www.bostonti.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
